share_log

DexCom | 10-Q: Q2 2024 Earnings Report

DexCom | 10-Q: Q2 2024 Earnings Report

德康醫療 | 10-Q:2024財年二季報
美股SEC公告 ·  2024/07/26 05:19

牛牛AI助理已提取核心訊息

DexCom reported strong Q2 2024 financial results with revenue reaching $1.00 billion, up 15% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 24% to $143.5 million, while operating income grew 23% to $158.0 million. Gross profit increased 15% to $626.7 million with a 62.4% margin.The company's growth was primarily fueled by its expanding worldwide customer base, having added approximately 600,000 net users in 2023. U.S. revenue grew 19% to $731.9 million, representing 73% of total revenue, while international revenue increased 7% to $272.4 million. Disposable sensor and other revenue comprised 94% of total revenue, up from 89% in the prior year period.Looking ahead, DexCom maintains strong liquidity with $3.12 billion in cash and investments. The company announced a new $750 million share repurchase program through June 2025, demonstrating confidence in its financial position. Management continues to focus on expanding global operations through investments in manufacturing facilities in Malaysia and Ireland to meet growing product demand.
DexCom reported strong Q2 2024 financial results with revenue reaching $1.00 billion, up 15% year-over-year, driven by increased sales volume of disposable sensors. Net income rose 24% to $143.5 million, while operating income grew 23% to $158.0 million. Gross profit increased 15% to $626.7 million with a 62.4% margin.The company's growth was primarily fueled by its expanding worldwide customer base, having added approximately 600,000 net users in 2023. U.S. revenue grew 19% to $731.9 million, representing 73% of total revenue, while international revenue increased 7% to $272.4 million. Disposable sensor and other revenue comprised 94% of total revenue, up from 89% in the prior year period.Looking ahead, DexCom maintains strong liquidity with $3.12 billion in cash and investments. The company announced a new $750 million share repurchase program through June 2025, demonstrating confidence in its financial position. Management continues to focus on expanding global operations through investments in manufacturing facilities in Malaysia and Ireland to meet growing product demand.
德康醫療發佈了2024年第二季度強勁的財務業績,營業收入達到10億美金,同比增長15%,主要得益於一次性傳感器的銷售量增加。凈利潤上漲24%,達到14350萬美元,而營業利潤增長23%,達到15800萬美元。毛利潤增加15%,達到62670萬美元,利潤率爲62.4%。公司的增長主要得益於其全球客戶基礎的擴展,2023年淨用戶數增加了約600,000人。美國的營業收入增長19%,達到73190萬美元,佔總營業收入的73%,而國際營業收入增長7%,達到27240萬美元。一一次性傳感器和其他收入佔總收入的94%,高於去年同期的89%。展望未來,德康醫療保持強勁的流動性,現金和投資總額爲31.2億美金。公司宣佈了一項新的75000萬美元的股票回購計劃,直到2025年6月,顯示出對其財務狀況的信心。管理層繼續專注於通過在馬來西亞和愛爾蘭投資製造設施來擴大全球業務,以滿足日益增長的產品需求。
德康醫療發佈了2024年第二季度強勁的財務業績,營業收入達到10億美金,同比增長15%,主要得益於一次性傳感器的銷售量增加。凈利潤上漲24%,達到14350萬美元,而營業利潤增長23%,達到15800萬美元。毛利潤增加15%,達到62670萬美元,利潤率爲62.4%。公司的增長主要得益於其全球客戶基礎的擴展,2023年淨用戶數增加了約600,000人。美國的營業收入增長19%,達到73190萬美元,佔總營業收入的73%,而國際營業收入增長7%,達到27240萬美元。一一次性傳感器和其他收入佔總收入的94%,高於去年同期的89%。展望未來,德康醫療保持強勁的流動性,現金和投資總額爲31.2億美金。公司宣佈了一項新的75000萬美元的股票回購計劃,直到2025年6月,顯示出對其財務狀況的信心。管理層繼續專注於通過在馬來西亞和愛爾蘭投資製造設施來擴大全球業務,以滿足日益增長的產品需求。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。